Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 1534 | 6.95 |
09:36 ET | 1900 | 6.95 |
09:38 ET | 200 | 6.92 |
09:39 ET | 1300 | 6.94 |
09:41 ET | 100 | 6.95 |
09:43 ET | 100 | 6.92 |
09:45 ET | 350 | 6.98 |
09:48 ET | 735 | 6.98 |
09:56 ET | 100 | 6.98 |
09:57 ET | 100 | 6.98 |
09:59 ET | 100 | 6.99 |
10:01 ET | 2721 | 7.0078 |
10:06 ET | 100 | 7.06 |
10:08 ET | 1100 | 7.06 |
10:10 ET | 500 | 7.005 |
10:12 ET | 100 | 7.06 |
10:14 ET | 400 | 7.07 |
10:15 ET | 1000 | 7.06 |
10:17 ET | 900 | 7.16 |
10:19 ET | 300 | 7.19 |
10:24 ET | 2200 | 7.18 |
10:26 ET | 2075 | 7.23 |
10:30 ET | 300 | 7.24 |
10:33 ET | 200 | 7.27 |
10:35 ET | 300 | 7.27 |
10:37 ET | 1200 | 7.2456 |
10:39 ET | 200 | 7.245 |
10:42 ET | 100 | 7.245 |
10:44 ET | 500 | 7.19 |
10:46 ET | 100 | 7.18 |
10:51 ET | 1100 | 7.165 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 207.3M | -4.2x | --- |
Prelude Therapeutics Inc | 204.9M | -1.9x | --- |
Skye Bioscience Inc | 212.2M | -1.6x | --- |
Fractyl Health Inc | 212.7M | -2.6x | --- |
Rezolute Inc | 216.3M | -3.6x | --- |
Gossamer Bio Inc | 217.1M | -0.9x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.3M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -4.2x |
Price/Sales (TTM) | 2,559.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.